triazoles has been researched along with tenofovir in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.38) | 29.6817 |
| 2010's | 30 (71.43) | 24.3611 |
| 2020's | 11 (26.19) | 2.80 |
| Authors | Studies |
|---|---|
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 1 |
| Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 1 |
| Kaptur, PE; Mertenskoetter, T | 1 |
| Férir, G; Palmer, KE; Schols, D | 1 |
| Chaiken, I; Fletcher, P; Gopi, H; Krebs, FC; Martin-Garcia, J; McFadden, K; Pirrone, V; Rajagopal, S; Rossi, F; Shattock, RJ; Umashankara, M | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Fang, J; Jadhav, PR | 1 |
| Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Bennett, LJ; Grooms-Williams, TW; Hamorsky, KT; Husk, AS; Matoba, N; Palmer, KE | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Binet, L; Djerada, Z; Feliu, C; Gozalo, C; Lamiable, D; Marty, H; Millart, H; Robinet, A; Tournois, C; Vautier, D | 1 |
| McGowan, I | 1 |
| Achhra, AC; Boyd, MA; Cooper, DA; Kelleher, AD; Law, MG; Matthews, GV | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C | 1 |
| De La Mata, FJ; Gómez, R; Jiménez, JL; Muñoz-Fernández, MÁ; Sánchez-Rodríguez, J; Sepúlveda-Crespo, D; Serramía, MJ | 1 |
| Berzins, B; Brown, T; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, A; Ofotokun, I; Ribaudo, H; Robertson, K; Taiwo, BO; Tsibris, A | 1 |
| Anderson, PL; Bushman, LR; Chuong, D; Dobard, CW; Garcia-Lerma, JG; Hanson, D; Heneine, W; McGowan, I; Pau, CP; Rohan, L; Sharma, S; Taylor, A; Wang, L | 1 |
| Chen, J; Li, L; Qin, C; Ren, Y; Wan, Y; Wang, J; Wang, W; Wei, Q; Xu, J; Zhang, X | 1 |
| Golan-Paz, S; Jiang, Y; Ramanathan, R; Read, B; Woodrow, KA | 1 |
| Allmon, A; Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Mollan, KR; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N | 1 |
| Baum, MM; Butkyavichene, I; Churchman, SA; Easley, JT; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Smith, TJ; Yang, F | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Berzins, B; Brown, TT; Chan, ES; Eron, JJ; Lee, A; Miyahara, S; Robertson, KR; Rusin, D; Taiwo, BO | 1 |
| Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M | 1 |
| Blakney, AK; Jiang, Y; Little, AB; Woodrow, KA | 1 |
| Behm, MO; Fackler, P; Levine, V; Liu, R; Panebianco, D; Yee, KL | 1 |
| Deeks, ED | 1 |
| Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y | 1 |
| Cahn, P; Hanna, G; Hwang, C; Kumar, S; Martin, E; Molina, JM; Orkin, C; Rodgers, A; Sax, P; Squires, K; Teppler, H; Thompson, M; Xu, X | 1 |
| Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A | 1 |
| DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ | 1 |
| Alegete, P; Kancherla, P; Kokkirala, TK; Suryakala, D | 1 |
| Godela, R; Gummadi, S | 1 |
| Antinori, S; Baldelli, S; Bisinella, GC; Cattaneo, D; Cossu, MV; Fusi, M; Gervasoni, C; Meraviglia, P; Micheli, V; Resnati, C; Vimercati, S | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
4 review(s) available for triazoles and tenofovir
| Article | Year |
|---|---|
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; Female; HIV Infections; Humans; Male; Maraviroc; Organophosphonates; Pyridines; Pyrimidines; Tenofovir; Triazoles; Urea | 2011 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
Doravirine: First Global Approval.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles | 2018 |
16 trial(s) available for triazoles and tenofovir
| Article | Year |
|---|---|
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Receptors, CCR5; Statistics as Topic; Tenofovir; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pelvic Bones; Tenofovir; Triazoles | 2015 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Neurocognition with maraviroc compared with tenofovir in HIV.
Topics: Adult; AIDS-Related Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cognition; Cyclohexanes; Double-Blind Method; Female; HIV Infections; Humans; Male; Maraviroc; Neuropsychological Tests; Placebos; Tenofovir; Treatment Outcome; Triazoles; United States | 2016 |
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2016 |
The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.
Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles | 2017 |
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult | 2019 |
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Topics: Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Pyridones; Tenofovir; Triazoles | 2020 |
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles | 2019 |
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult | 2020 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2021 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
22 other study(ies) available for triazoles and tenofovir
| Article | Year |
|---|---|
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Topics: Adenine; Algal Proteins; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclohexanes; Drug Synergism; Enfuvirtide; Genotype; HIV Envelope Protein gp41; HIV-1; Humans; Lectins; Leukocytes, Mononuclear; Maraviroc; Microbial Sensitivity Tests; Organophosphonates; Peptide Fragments; Plant Lectins; Tenofovir; Triazoles | 2011 |
Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Therapy, Combination; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Organophosphonates; Peptides; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Replication | 2012 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia | 2012 |
Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
Topics: Adenine; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Chromatography, Affinity; Cyclohexanes; Drug Combinations; Drug Synergism; Genetic Vectors; HIV Antibodies; HIV Envelope Protein gp120; HIV-1; Humans; Immunoglobulin G; Maraviroc; Neutralization Tests; Nicotiana; Organophosphonates; Plant Lectins; Recombinant Proteins; Tenofovir; Tobamovirus; Triazoles | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Topics: Adenine; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Mass Spectrometry; Nitriles; Organophosphonates; Proline; Pyridazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tandem Mass Spectrometry; Tenofovir; Time Factors; Triazoles | 2013 |
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; Dideoxynucleosides; Feasibility Studies; Female; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Ritonavir; Tenofovir; Triazoles | 2014 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Chemoprevention; Chromatography, Liquid; Cyclohexanes; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Maraviroc; Middle Aged; Organ Culture Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Triazoles; Vagina; Viral Load; Young Adult | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexanes; Dendrimers; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Inbred BALB C; Mucous Membrane; Organophosphonates; Silanes; Software; Tenofovir; Triazoles; Vagina | 2015 |
Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Cross-Over Studies; Cyclohexanes; Disease Models, Animal; Disease Transmission, Infectious; Gels; Macaca; Maraviroc; Placebos; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Treatment Outcome; Triazoles | 2015 |
Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses.
Topics: Administration, Rectal; Animals; Anti-Infective Agents, Local; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Gene Expression Profiling; Humans; Immunity, Cellular; Macaca mulatta; Maraviroc; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Peptides; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Survival Rate; Tenofovir; Triazoles; Viral Load | 2016 |
Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Biophysical Phenomena; Body Fluids; Cell Line; Cell Survival; Chemoprevention; Cryoelectron Microscopy; Cyclohexanes; Detergents; Drug Liberation; Female; HIV-1; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Lipid Bilayers; Liposomes; Maraviroc; Mice, Inbred C57BL; Mucous Membrane; Nanoparticles; Small Molecule Libraries; Tenofovir; Triazoles | 2016 |
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.
Topics: Adult; Anti-HIV Agents; Biomarkers; Body Fluids; Cervix Uteri; Clinical Trials as Topic; Cyclohexanes; Emtricitabine; Female; Healthy Volunteers; Humans; Maraviroc; Raltegravir Potassium; Rectum; Tenofovir; Triazoles; Vagina | 2016 |
Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Cyclohexanes; Delayed-Action Preparations; Drug Combinations; Female; HIV Infections; Humans; Maraviroc; Models, Animal; Primary Prevention; Sheep; Tenofovir; Triazoles; Vagina | 2016 |
In vitro-ex vivo correlations between a cell-laden hydrogel and mucosal tissue for screening composite delivery systems.
Topics: Animals; Chemistry, Pharmaceutical; Cyclohexanes; Delayed-Action Preparations; Drug Delivery Systems; Female; Hydrogel, Polyethylene Glycol Dimethacrylate; Lactic Acid; Macaca nemestrina; Maraviroc; Methacrylates; Mucous Membrane; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Primates; Pyrimidines; Tenofovir; Triazoles; Vagina | 2016 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Lamivudine; Limit of Detection; Linear Models; Pyridones; Reproducibility of Results; Tablets; Tenofovir; Triazoles | 2021 |
A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets.
Topics: Chromatography, High Pressure Liquid; Lamivudine; Pyridones; Tablets; Tenofovir; Triazoles | 2021 |
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens.
Topics: Anti-HIV Agents; HIV Infections; Humans; Pyridones; Tenofovir; Triazoles | 2021 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |